Publications from China in Epilepsia


To the Editors:

Epilepsia, as “the journal of the International League Against Epilepsy” (ILAE), is the leading and most widely read medical journal in epilepsy research. Since the first publication in 1909, the Journal has been aiming to publish the highest quality research and educational resources on epilepsy, and to make these materials available to people worldwide who need that knowledge.

However, publications from China are limited in this respected journal. Recent search was performed in Wiley Online Library up to July 24, 2013. The search strategy was Epilepsia in Publication Titles AND China (Hong Kong and Taiwan) in Author Affiliation without any limits. Moreover, Thomson Reuters' Science Citation Index via Web of Science was searched for supplements with the same terms. There were in total 149 publications contributed by authors from China (Fig. 1). Although a little more than those from Korea (92), there is a big gap in the numbers of publications between those from China and those from Japan (667) or the United States (3,446), using the same search strategy in Wiley Online Library. In China, with the largest population worldwide, there are so many epilepsy patients that doctors, patients, the government, and the public all need better understanding to treat epilepsy and related disorders. Chinese authors should be encouraged to publish more of their works in Epilepsia and other related international journals. This is a good way to present the situation of epilepsy in China to the world and to communicate with international colleagues and benefit the patients with epilepsy.

Figure 1.

Publications in Epilepsia from China, beginning in 1983 and up to July 2013.

We are inspired by an increasing number of publications in regular issues of Epilepsia from China in recent years. In addition in the Web of Science, 342 posters from China submitted to international epilepsy congresses were included in Epilepsia. More and more Chinese researchers initiate or participate in clinical trials and present data on new drugs and treatments. Some prospective, randomized, double-blind, and placebo-controlled studies that have been published in Epilepsia were contributed by authors from China. We hope that we will see more excellent research from China published in Epilepsia in the near future.


Neither of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.